|
Optimizing management of the oncological patient with pulmonary embolism: Validation of the epiphany index—PERSEO study. |
|
|
Consulting or Advisory Role - KyowaKirin |
Research Funding - Leo Pharma (Inst) |
Travel, Accommodations, Expenses - LEO Pharma; MSD Oncology; Sanofi; Sanofi; SERVIER |
Other Relationship - Acraf; KyowaKirin; Mylan; Rovi; Sanofi |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - ROVI |
|
|
Travel, Accommodations, Expenses - Leo Pharma; Roche |
|
|
Travel, Accommodations, Expenses - ROVI |
|
|
Consulting or Advisory Role - Amgen; Sanofi |
Speakers' Bureau - Celgene; Lilly; Roche; Sanofi; SERVIER |
|
|
No Relationships to Disclose |
|
|
Honoraria - LEO Pharma; Rovi; Sanofi/Aventis |
Consulting or Advisory Role - LEO Pharma; Sanofi/Aventis |
Speakers' Bureau - LEO Pharma; rovi; Sanofi/Aventis |
Travel, Accommodations, Expenses - LEO Pharma; rovi; Sanofi/Aventis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer; Leo Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Amgen; Sanofi |
Travel, Accommodations, Expenses - Amgen; Leo Pharma; Roche; Sanofi |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Pfizer; Celgene; Daiichi Sankyo; Halozyme; LEO Pharma; Sanofi |
|
Research Funding - LEO Pharma; Sanofi |
Patents, Royalties, Other Intellectual Property - Risk assessment model in venous thromboembolism in cancer patients |
Travel, Accommodations, Expenses - Celgene; Merck Serono; Roche |
|
|
Other Relationship - IPSEN |
|
|
Consulting or Advisory Role - Pfizer; Roche/Genentech |
|
Research Funding - LEO Pharma (Inst) |
Travel, Accommodations, Expenses - Ipsen; Novartis; Roche/Genentech |